US Stocks Movement | BlossomHill Therapeutics (BLSM.US) Listed on US Stock Market, Shares Slightly Declined After Opening
As of press time, the stock has dropped more than 1%, trading at $15.8.
According to Jinse Finance APP, on Friday, BlossomHill Therapeutics (BLSM.US) debuted on the US stock market. As of press time, the stock was down over 1%, trading at $15.8. BlossomHill Therapeutics is headquartered in San Diego, California, and was founded in 2020. The company focuses on developing small molecule cancer drugs by identifying structural weaknesses in existing therapies and designing new compounds to overcome these shortcomings. Its core candidate drug, BH-30643, targeting EGFR-mutant non-small cell lung cancer (NSCLC), is currently undergoing global Phase I/II clinical trials. The company plans to hold an end-of-Phase I meeting with the US Food and Drug Administration (FDA) in the fourth quarter of 2026 to discuss the recommended Phase II dosing regimen and potential accelerated approval pathways for certain patients.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bearish to 159! Ahead of Friday's Bank of Japan decision, Wall Street strategists collectively bet on a weaker yen
The swap market has fully priced in expectations of a Bank of Japan rate hike. Strategists warn that if the central bank's hawkish stance falls short of estimates, it could trigger a sell-off in the yen, with the exchange rate potentially dipping towards the 159 level in the short term.
Iran’s IRGC claims attack on Togolese oil tanker for 'illegal transit' in Strait of Hormuz
RBA's Bullock: At August board meeting, risks to outlook were skewed to the upside
Lucid (LCID.US) stock price surged over 12%! CEO announces completion of restructuring advisor collaboration, roadmap to profitability emerges
The CEO of Lucid Group Inc. stated that the electric vehicle manufacturer has completed its collaboration with a restructuring advisory team, indicating that the troubled company now has a clearer path to turn around its operations.
Crypto prices
More
